Physician profile
Marc S Effron
NPI 1023218815
$1,595.36
in general payments reported to CMS, 2019-2025
23 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $136 · 2021: $119 · 2022: $194 · 2023: $294 · 2024: $381 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $441.63 | 2019-2024 | Octrode, Proclaim, Eterna |
| Painteq LLC | $152.10 | 2024 | Painteq |
| Vertiflex, INC. | $118.74 | 2019 | |
| Nalu Medical, INC. | $88.79 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic Vascular, INC. | $87.51 | 2019 | |
| Nevro Corp. | $86.46 | 2020-2023 | Senza |
| Merz Pharmaceuticals, LLC | $69.66 | 2025 | Xeomin |
| Abbvie INC. | $68.12 | 2023 | Qulipta, Ubrelvy |
| Providence Medical Technology, INC. | $59.61 | 2024 | |
| Vertos Medical, INC. | $59.34 | 2021-2022 | |
| Relievant Medsystems, INC. | $46.92 | 2023 | Intracept |
| Medtronic, INC. | $45.66 | 2025 | Inceptiv |
| Arbor Pharmaceuticals, INC. | $37.02 | 2019-2020 | |
| Si-Bone, INC. | $34.93 | 2022 | |
| Spr Therapeutics, INC | $31.53 | 2022-2024 | Sprint Pns System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $31.11 | 2022-2023 | Seglentis |
| Depuy Synthes Sales INC. | $30.37 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $22.99 | 2025 | |
| Appliedvr INC | $19.16 | 2025 | Relievrx |
| Collegium Pharmaceutical, INC. | $17.77 | 2023 | Xtampza |
| Stimwave Technologies Incorporated | $17.58 | 2020 | |
| Allergan, INC. | $14.48 | 2021 | |
| Boston Scientific Corporation | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Effron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.